Peter Clayton
Great Ormond Street Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peter Clayton.
American Journal of Human Genetics | 2000
M. Witsch-Baumgartner; B.U. Fitzky; M. Ogorelkova; H.G. Kraft; F.F. Moebius; H. Glossmann; U. Seedorf; G. Gillessen-Kaesbach; Georg F. Hoffmann; Peter Clayton; Richard I. Kelley; Gerd Utermann
Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive malformation syndrome, ranges in clinical severity from mild dysmorphism and moderate mental retardation to severe congenital malformation and intrauterine lethality. Mutations in the gene for Δ7-sterol reductase (DHCR7), which catalyzes the final step in cholesterol biosynthesis in the endoplasmic reticulum (ER), cause SLOS. We have determined, in 84 patients with clinically and biochemically characterized SLOS (detection rate 96%), the mutational spectrum in the DHCR7 gene. Forty different SLOS mutations, some frequent, were identified. On the basis of mutation type and expression studies in the HEK293-derived cell line tsA-201, we grouped mutations into four classes: nonsense and splice-site mutations resulting in putative null alleles, missense mutations in the transmembrane domains (TM), mutations in the 4th cytoplasmic loop (4L), and mutations in the C-terminal ER domain (CT). All but one of the tested missense mutations reduced protein stability. Concentrations of the cholesterol precursor 7-dehydrocholesterol and clinical severity scores correlated with mutation classes. The mildest clinical phenotypes were associated with TM and CT mutations, and the most severe types were associated with 0 and 4L mutations. Most homozygotes for null alleles had severe SLOS; one patient had a moderate phenotype. Homozygosity for 0 mutations in DHCR7 appears compatible with life, suggesting that cholesterol may be synthesized in the absence of this enzyme or that exogenous sources of cholesterol can be used.
42nd Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2014
Jins Kallampallil; Ksenija Acimovic; Daniel Hanson; Andrew Whatmore; Peter Clayton
Relative phosphorylation of AKT was assessed by western blotting and comparisons made both within and between cell lines. In view of this altered growth factor signalling, we have investigated the activation of AKT by IGF-2 and Insulin. Relative pAKT was reduced in 3-M fibroblasts compared to normal cells when stimulated with either insulin (p = 0.048) or IGF-2 (p = 0.033) (Fig. 2). For both treatments, CUL7-/and OBSL1-/cells had a markedly lower activation of pAKT than did CCDC8-/cells. CUL7-/cells had an earlier activation in response to insulin (p = 0.016) than other cell types.
American Journal of Human Genetics | 2013
Sarah E. Flanagan; Weijia Xie; Richard Caswell; Annet Damhuis; Christine Vianey-Saban; Teoman Akcay; Feyza Darendeliler; Firdevs Bas; Ayla Güven; Zeynep Siklar; Gönül Öcal; Merih Berberoglu; Nuala Murphy; Maureen J. O'Sullivan; Andrew Green; Peter Clayton; Indraneel Banerjee; Khalid Hussain; Michael N. Weedon; Sian Ellard
Endocrine Abstracts | 2018
Peter Clayton; Adam Stevens; Philip Murray; Terence Garner
Endocrine Abstracts | 2018
Laila Al-Hashmi; Claire Manfredonia; Indi Banerjee; Lesley Tetlow; Philip Murray; Peter Clayton
45th Meeting of the British Society for Paediatric Endocrinology and Diabetes | 2017
Reena Perchard; Lucy Higgins; Edward Johnstone; Peter Clayton
Archive | 2016
Reena Perchard; Philip Murray; Anthony Payton; Peter Clayton
Archive | 2016
Philip Murray; Adam Stevens; Ekaterina Koledova; Pierre Chatelain; Peter Clayton
55th Annual ESPE | 2016
Sam Parsons; Adam Stevens; Andrew Whatmore; Philip Murray; Peter Clayton
Archive | 2015
Leonibus Chiara De; Philip Murray; Dan Hanson; Adam Stevens; Peter Clayton